International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 313-314 , 1 October 2008

Isn't It Reasonable to Ask for Fraction Numbers?

  • Jack F. Fowler, D.Sc., Ph.D., F.Inst.P, F.R.C.R., F.A.C.R

      Affiliations

    • Corresponding Author InformationReprint requests to: Jack F. Fowler, D.Sc., Ph.D., Flat 1, 150 Lambeth Road, London SE1 7DF, United Kingdom. Tel: (+44) 0-207-207-7997

Received 4 June 2008 ,Accepted 12 June 2008.

References 

  1. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337
  2. Williams SG, Taylor JMG, Liu H, et al. Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:23–33
  3. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689
  4. Kuban DA, Tucker SL, Lei Dong, et al. Long-term results of the MD Anderson Randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  5. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  6. Cheung R, Tucker SL, Lee AK, et al. Dose–response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:993–1002
  7. Morgan PB, Hanlon AE, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1074–1081
  8. Kälkner KM, Wahlgren T, Rydberg M, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol. 2007;46:909–917
  9. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using coformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048–1055
  10. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533

 Conflict of interest: none.

PII: S0360-3016(08)02501-7

doi: 10.1016/j.ijrobp.2008.06.1494

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 313-314 , 1 October 2008

Article Tools